

**REMARKS**

Claims 1-2, 4-10, 15-17, 19, 27-31, 33, 41, 46-59, and 74-82 are pending in the application. The U.S. Patent and Trademark Office (“the Office”) has required restriction to one of the following groups of claims under 35 U.S.C. §§ 121 and 372:

- Group 1: claims 5 and 52, drawn to “compositions comprising CR2 and DAF”;
- Group 2: claim 6, drawn to “compositions comprising CR2 and SEQ ID NO:10”;
- Group 3: claim 7, drawn to “compositions comprising CR2 and SEQ ID NO:6”;
- Group 4: claims 8-10, 17, 52, and 54, drawn to “compositions comprising CR2 and CD59”;
- Group 5: claims 15, 16, 52, and 53, drawn to “compositions comprising CR2 and” Crry;
- Group 6: claims 27, 28, and 52, drawn to “compositions comprising CR2 and CVF”;
- Group 7: claims 29, and 74-77, drawn to “compositions comprising CR2 and Ig”;
- Group 8: claims 30-31, 33, 41, 56-58, and 78, drawn to “a method of treatment using compositions comprising CR2 and DAF”;
- Group 9: claims 30-31, 33, 41, 56-58, and 78, drawn to “a method of treatment using compositions comprising CR2 and CD59”;
- Group 10: claims 30-31, 33, 41, 56-58, and 78, drawn to “a method of treatment using compositions comprising CR2 and” Crry;
- Group 11: claims 30-31, 33, 41, 56-58, and 78, drawn to “a method of treatment using compositions comprising CR2 and CVF”;
- Group 12: claims 79-82, drawn to “a method of treatment using compositions comprising CR2 and” Ig;
- Group 13: claim 46, drawn to a method for decreasing complement-mediated damage using compositions comprising CR2 and DAF.
- Group 14: claim 46, drawn to “a method for decreasing complement-mediated damage using compositions comprising CR2 and CD59”;
- Group 15: claim 46, drawn to “a method for decreasing complement-mediated damage using compositions comprising CR2 and” Crry”;
- Group 16: claim 46, drawn to “a method for decreasing complement-mediated damage using compositions comprising CR2 and CVF”;

Group 17: claim 47, drawn to “a method for increasing complement-mediated damage using compositions comprising CR2 and DAF”;

Group 18: claim 47, drawn to “a method for increasing complement-mediated damage using compositions comprising CR2 and CD59”;

Group 19: claim 47, drawn to “a method for increasing complement-mediated damage using compositions comprising CR2 and” Cry.

Group 20: claim 47, drawn to “a method for increasing complement-mediated damage using compositions comprising CR2 and CVF”;

Group 21: claim 55, drawn to “a method for targeting a modulator using compositions comprising CR2 and DAF”;

Group 22: claim 55, drawn to “a method for targeting a modulator using compositions comprising CR2 and CD59”;

Group 23: claim 55, drawn to a method for targeting a modulator using compositions comprising CR2 and” Cry.

Group 24: claim 55, drawn to “a method for targeting a modulator using compositions comprising CR2 and CVF.”

Office Action, pp. 2-3. The Office further stated that claims 1-2, 4, 19, 48-51, and 78 link any one of inventions 1-7, 8-12, 13-16, 17-20, or 21-24. *Id.* at p. 4.

Applicants hereby provisionally elect to prosecute Group 4, claims 8-10, 17, 52, and 54, drawn to “compositions comprising CR2 and CD59,” without traverse.

Applicants expressly reserve the right to pursue any non-elected subject matter in one or more divisional applications and/or to request rejoinder of appropriate claims (*e.g.*, method claims) once the subject matter of the elected claims is found allowable.

**CONCLUSION**

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **577712000200**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 15, 2009

Respectfully submitted,

Electronic Signature: /David C. Hoffman/  
David C. Hoffman  
Registration No.: 59,821

MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-4019